mike
bray
craig
rayner
david
jan
kyli
wagstaff
cali
et
al
monash
univers
australia
recent
publish
paper
antivir
research
report
ivermectin
medic
wide
use
treatment
certain
parasit
diseas
human
livestock
anim
inhibit
replic
cell
cultur
despit
author
cautiou
conclus
ivermectin
warrant
investig
possibl
benefit
human
paper
excit
widespread
interest
medic
veterinari
websit
often
incorrectli
describ
drug
treatment
cure
inappropri
statement
led
warn
us
fda
ivermectin
veterinari
product
use
human
therapi
http
fda
messag
also
explain
vitro
studi
report
avr
commonli
use
earli
stage
drug
develop
paper
cali
et
al
also
elicit
two
letter
editor
print
follow
author
respons
letter
reader
awar
neither
letter
respons
peerreview
appropri
caution
use
quot
cite
cali
l
druce
jd
catton
mg
jan
da
wagstaff
km
fdaapprov
drug
ivermectin
inhibit
replic
vitro
antivir
re
apr
recent
cali
et
al
report
vitro
activ
ivermectin
follow
singl
addit
verohslam
cell
suggest
data
demonstr
ivermectin
worthi
consider
possibl
antivir
isol
vitro
data
robust
encourag
report
includ
correl
vitro
find
clinic
achiev
plasma
relevantli
lung
concentr
would
permit
determin
whether
macrocycl
lacton
specif
case
ivermectin
genuin
therapeut
option
cali
et
al
bath
verohslam
cell
ivermectin
concentr
hour
postinfect
isol
conclus
experi
rna
determin
rtpcr
day
supernat
cell
pellet
experi
author
note
reduct
viral
rna
ivermectin
versu
dmso
control
supernat
releas
virion
cell
associ
viral
rna
total
viru
respect
also
describ
hour
reduct
viral
rna
mainten
effect
hour
addit
experi
conduct
serial
dilut
ivermectin
establish
concentrationrespons
profil
author
describ
ivermectin
potent
inhibitor
ic
determin
approxim
condit
sought
examin
clinic
relev
concentr
evalu
vitro
experi
may
achiev
ivermectin
dose
practic
order
assist
priorit
ongo
effort
find
therapeut
may
effect
ivermectin
one
human
import
medicin
extens
use
neglect
tropic
diseas
singl
oral
dose
result
mean
peak
plasma
concentr
approxim
ngml
phase
studi
dose
administ
fast
state
follow
standard
highfat
meal
smit
et
al
report
ivermectin
administ
oral
result
maximum
median
concentr
cmax
plasma
ngml
rel
rapid
clearanc
halflif
approxim
hour
similar
yao
et
al
propos
potenti
hydroxychloroquin
treat
appli
physiologicbas
pharmacokinet
pbpk
model
ivermectin
use
simcyp
platform
explor
plasma
lung
concentr
rel
ic
valu
determin
vitro
ivermectin
pbpk
model
initi
develop
facilit
drug
develop
parasit
diseas
includ
onchocerciasi
full
model
allow
predict
tissu
drug
concentr
model
independ
verifi
predict
versu
observ
plasma
profil
ivermectin
across
clinic
studi
mectizan
nda
well
align
indic
base
model
well
defin
furthermor
pbpk
model
abl
predict
ivermectin
exposur
plasma
adipos
skin
within
observ
data
patient
infect
onchocerca
volvulu
simul
perform
use
simcyp
simul
version
releas
ten
virtual
trial
subject
age
year
femal
simul
use
simneurcaucas
popul
simul
high
dose
ivermectin
administ
oral
daili
day
virtual
studi
carri
day
dose
fed
state
fraction
unbound
plasma
lung
simul
mean
system
plasma
lung
tissu
concentr
shown
figur
pharmacodynam
respons
gener
achiev
ensur
appropri
durat
exposur
minimum
therapeut
concentr
site
action
even
gener
assumpt
clinic
translat
vitro
higher
day
plasma
lung
tissu
simul
cmax
respect
follow
high
dose
ivermectin
regimen
dose
daili
day
dose
scenario
ignor
consist
exposur
exce
highest
regulatori
approv
dose
ivermectin
singl
dose
treatment
strongyloidiasi
cali
et
al
cite
import
regulatori
approv
ivermectin
key
part
rational
evalu
howev
rigor
data
review
reassur
stringent
regulatori
author
review
appli
current
approv
dose
clinic
pharmacolog
toxicolog
margin
includ
preand
postnat
carcinogen
studi
would
therefor
need
recalcul
realiti
result
unravel
support
packag
data
could
result
lengthi
delay
support
data
revis
rerun
understand
face
devast
pandem
medic
societ
imper
great
enthusiasm
promis
news
treatment
pick
support
best
therapi
prevent
tackl
pandem
head
one
scientif
commun
urgent
prioriti
assist
process
clinic
pharmacolog
relev
vitro
vivo
find
includ
vitro
promis
lead
clinic
failur
vast
major
case
volatil
environ
current
pandem
critic
sensit
implic
commun
appli
resourc
compound
like
succeed
small
window
exist
current
data
relev
human
need
confirm
effect
concentr
assess
class
macrocycl
lacton
similar
target
interact
understand
relev
concentr
use
vitro
like
achiev
site
action
within
dose
rang
consid
well
toler
altern
rout
could
also
consid
although
present
new
formul
safeti
challeng
model
simul
approach
integr
vitro
find
vivo
situat
may
serv
priorit
exist
drug
candid
repurpos
fund
inform
fund
provid
write
short
commun
guzzo
c
et
al
safeti
toler
pharmacokinet
editor
context
repositioningrepurpos
strategi
urgent
unmet
medic
need
variou
drug
propos
treatment
pandem
diseas
caus
lima
case
broadspectrum
macrocycl
lacton
ivermectin
report
base
data
show
ivermectin
inhibit
replic
vitro
howev
vitro
activ
occur
much
higher
concentr
ic
low
nanomolar
concentr
effect
mani
nematod
speci
geari
obtain
usual
dose
micromolar
concentr
also
higher
therapeut
peak
plasma
concentr
nm
measur
human
treat
onchocerciasi
control
standard
dose
apud
shu
et
al
even
high
daili
dose
cmax
ngml
obtain
pkpd
model
smit
et
al
previous
show
pimenta
et
al
ivermectin
nonselect
inhibitor
three
import
mammalian
ptype
atpas
serca
na
k
atpas
h
k
atpas
similar
micromolar
concentr
ic
concern
put
import
advers
effect
drug
could
produc
higher
usual
dose
would
necessari
treat
patient
result
phase
studi
absolut
need
use
ivermectin
sinc
recent
metaanalysi
conclud
enough
data
support
recommend
use
higherthanapprov
dose
navarro
et
al
laboratori
biochem
molecular
pharmacolog
institut
biomed
scienc
feder
univers
rio
de
janeiro
rio
de
janeiro
brazil
